Arrowhead Research | ARWR - Loan Capital


Arrowhead Research reported $1.23B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
TG Therapeutics USD 745.39M 247K Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 77.54M 4.59M Jun/2026